GlaxoSmithKline: Neoplasms trials

The registry lists 150 Neoplasms studies with GlaxoSmithKline as lead sponsor. 6 are open to participants now and 60 have results posted.

Phase 1 95Phase 2 36Phase 3 7Phase 4 2No phase 17(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid TumorsRecruitingNCT07438782Phase 1
• A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsRecruitingNCT07277270Phase 1
• A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsRecruitingNCT07213609Phase 1/2
• A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)RecruitingNCT06796907Phase 1/2
• A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
• A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)RecruitingNCT06431594Phase 1
• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3CompletedNCT06926673Phase 2Results posted
• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2TerminatedNCT06790303Phase 2Results posted
• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1CompletedNCT05553808Phase 2Results posted
• Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy TrialsTerminatedNCT05100316Phase 2Results posted
• Molecular Disease Characterization Initiative (MDCI)TerminatedNCT04772053Phase 2Results posted
• Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)TerminatedNCT04544995Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial CancerTerminatedNCT04349280Phase 1Results posted
• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT04128696Phase 3Results posted
• A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid TumorsTerminatedNCT03843359Phase 1Results posted
• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedNCT03739710Phase 2Results posted
• Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With PembrolizumabTerminatedNCT03709706Phase 1/2Results posted
• GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedNCT03693612Phase 1/2Results posted
• First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT03666988Phase 1Results posted
• Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedNCT03614728Phase 1/2Results posted
• Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid TumorsCompletedNCT03447314Phase 1Results posted
• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment PatientsCompletedNCT03359850Phase 1Results posted
• Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib CapsuleCompletedNCT03329001Phase 1Results posted
• Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsCompletedNCT03308942Phase 2Results posted
• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1Results posted
• Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsCompletedNCT03250832Phase 1Results posted
• Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple MyelomaTerminatedNCT03168438Phase 1Results posted
• Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell LiposarcomaCompletedNCT02992743Phase 2Results posted
• Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast CancerTerminatedNCT02964507Phase 1Results posted
• A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy SubjectsCompletedNCT02798978Phase 1Results posted
• An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's LymphomaCompletedNCT02783300Phase 1Results posted
• Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)CompletedNCT02723955Phase 1Results posted
• Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
• Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid TumorsTerminatedNCT02630251Phase 1Results posted
• Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02588612Phase 1Results posted
• GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)CompletedNCT02528357Phase 1Results posted
• Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or TrametinibTerminatedNCT02314143Phase 2Results posted
• Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate CancerCompletedNCT02215096Phase 1Results posted
• A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT02177812Phase 1Results posted
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaTerminatedNCT02082977Phase 1Results posted
• Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung CarcinomaTerminatedNCT02034123Phase 1Results posted
• Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid TumorsCompletedNCT01966445Phase 1Results posted
• A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract CancersCompletedNCT01943864Phase 2Results posted
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic MalignanciesCompletedNCT01943851Phase 2Results posted
• Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway SignalingCompletedNCT01868022Phase 1Results posted
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other CancersCompletedNCT01587703Phase 1Results posted
• A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial SarcomaCompletedNCT01343043Phase 1Results posted
• A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc IntervalCompletedNCT01328054Phase 4Results posted
• GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive MelanomaCompletedNCT01245062Phase 3Results posted
• Cancer in Patients With Gabapentin (GPRD)CompletedNCT01236053Results posted
• Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic CancerCompletedNCT01231581Phase 2Results posted
• A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) MelanomaCompletedNCT01227889Phase 3Results posted
• VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PKCompletedNCT01205230Phase 4Results posted
• Lapatinib in Combination With VinorelbineCompletedNCT01128543Phase 2Results posted
• Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) DrugsCompletedNCT01098500Results posted
• Carcinogenicity Study of BupropionCompletedNCT01077596Results posted
• Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF InhibitorCompletedNCT01037127Phase 2Results posted
• Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell LymphomaCompletedNCT01014208Phase 3Results posted
• Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory LeukemiasCompletedNCT00920140Phase 2Results posted
• Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT00823719Phase 2Results posted
• Study of GSK1363089 in Metastatic Gastric CancerCompletedNCT00725712Phase 2Results posted
• Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological TumorsCompletedNCT00561795Phase 2Results posted
• Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And LapatinibCompletedNCT00526669Phase 2Results posted
• Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric CancerCompletedNCT00486954Phase 3Results posted
• Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy ExistsTerminatedNCT00447226Phase 2Results posted
• Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical CancerCompletedNCT00430781Phase 2Results posted
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid TumorsActive, not recruitingNCT06077877Phase 1/2
• First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
• Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruitingNCT04446351Phase 1
• A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerActive, not recruitingNCT03981796Phase 3
• Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1aWithdrawnNCT03697824Phase 2
• Extended Access of Momelotinib in Adults With MyelofibrosisActive, not recruitingNCT03441113Phase 2
• Patient-Reported Outcome Measurement Information System (PROMIS) Physical FunctionCompletedNCT03351140
• Perceptions of Cell and Gene Therapies (CGT) for the Treatment of CancerCompletedNCT03336567
• Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid TumoursWithdrawnNCT02939846Phase 1
• A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingNCT02817633Phase 1
• Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsActive, not recruitingNCT02715284Phase 1
• A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing PotentialCompletedNCT02706535Phase 1
• Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With CancerCompletedNCT02476552Phase 1
• Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or AibrateroneWithdrawnNCT02380313Phase 1
• Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid TumorsCompletedNCT02345174Phase 1
• A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid TumorsWithdrawnNCT02292732Phase 1
• Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and MidazolamCompletedNCT02082665Phase 1
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid TumorsCompletedNCT02065063Phase 1
• Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of AfuresertibCompletedNCT02040480Phase 1
• A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung CancerWithdrawnNCT02034097Phase 2
• A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive TumorsCompletedNCT01954043Phase 1
• A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid TumorsCompletedNCT01938443Phase 1
• Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy VolunteersCompletedNCT01827644Phase 1
• A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive TumorsCompletedNCT01738451Phase 1
• A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor MalignanciesCompletedNCT01725100Phase 1
• A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212CompletedNCT01658553Phase 1
• Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) FormulationCompletedNCT01647659Phase 1
• A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid MalignanciesSuspendedNCT01604863Phase 1
• IMI PROTECT (Work Package 2): Calcium Channel Blockers and CancerCompletedNCT01587742
• A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid TumorsCompletedNCT01582997Phase 1
• A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor CancersCompletedNCT01476137Phase 1
• Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)TerminatedNCT01476085Phase 1
• Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast CancerCompletedNCT01462604
• Physician Liver Function Test (LFT) Monitoring for Tykerb PtsCompletedNCT01462552